In particular, treatment of melanoma with the use of Epacadostat (a selective inhibitor of IDO1) combined with pembrolizumab (an inhibitor of PD-1) does not offer significant advantages over placebo plus pembrolizumab (16). Here, IDO1 is linked to melanoma.